^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BCR-ABL1 T315I + ABL1 E255K

    i
    Other names: ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1, BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL
    Entrez ID:
    25; 613
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    CLAE regimen followed by allo-HSCT may be an effective salvage treatment option for R/R AL patients to prolong the overall survival.
    Journal • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • IL2 (Interleukin 2)
    |
    ABL1 T315I • ABL1 E255K • BCR-ABL1 T315I + ABL1 E255K
    |
    dasatinib • cytarabine • etoposide IV • methotrexate • cladribine • fludarabine IV • busulfan • cyclosporin A microemulsion